Royal Philips, a global provider in health technology, recently announced two new advances in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation.
The company’s artificial intelligence (AI)-enabled MRCAT Head and Neck radiotherapy application, allowing the use of MR as the primary imaging modality for radiotherapy planning in the treatment of soft tissue tumors in head and neck along with brain, pelvis and prostate, has received FDA 510(k) clearance and is commercially available.
Due to a recent development partnership with patient-positioning company MacroMedics, Philips has also announced compatibility of MacroMedics’ latest DSPS (double shell positioning system) positioning system with Philips MR Head Neck Coil.
This solution combines the superior soft tissue imaging capabilities and the high-resolution image quality of Philips’ head and neck coil with the comfort-enhancing and positional accuracy and stability features of MacroMedics’ mask. These developments aim to improve the accuracy of radiotherapy planning and simulation to help achieve better patient outcomes, enhance patient comfort, and offer the efficiency benefits of an MR-only workflow.
Marielle Philippens, associate professor of radiotherapy, Utrecht, Netherlands said, “With this innovative mask that fits into Philips’ head coil, we expect to acquire head and neck images for radiotherapy planning with diagnostic image quality and improved patient comfort.”
“With this innovative mask that fits into Philips’ head coil, we expect to acquire head and neck images for radiotherapy planning with diagnostic image quality and improved patient comfort,” said Philippens who is currently using the integrated Philips and MacroMedics solution.
Philips’ radiation oncology portfolio is designed to provide greater clarity by empowering oncologists with accurate image guidance, integrated workflows, and the versatility to deliver the precise, adaptive, personalized treatment every patient deserves. The company’s products and services are enhanced through strategic clinical and technology partnerships, vendor-neutral device integration, advanced imaging and AI algorithms to help physicians deliver more confident diagnoses and treatment pathways for patients.
During ASTRO 2022, Philips will also highlight its strategic partnership with Elekta in precise and personalized oncology care. Building on their successful collaboration to develop Elekta Unity, the world’s first high-field MR-linac (linear accelerator), the two companies are collaborating to further deliver image-guided adaptive treatment and oncology informatics solutions to personalize and improve cancer care.
Philips is showcasing its latest innovations in radiation oncology at ASTRO 2022 (October 23-26, San Antonio, Texas, U.S.), all of which are designed to help increase accuracy across imaging, planning, and treatment; improve patient and staff satisfaction; accelerate time to treatment; and maximize investment value. Visit Philips at ASTRO 2022 for more information on Philips’ radiation oncology innovations being highlighted at the event.